marketing authorization procedures for medicines within the EU.

UK Medicines and Medical Devices Act 2021: Regulates the oversight of medicines and medical devices in the UK post-Brexit.

For combination products, which typically consist of a drug/device or biologic/device pairing, additional guidance is necessary. The FDA’s Office of Combination Products (OCP) provides critical insights into how such products will be regulated, including the determination of the primary mode of action.

This regulatory framework is further supported by the EMA’s guidance on combination products, which outlines considerations for the assessment of combination therapies in the EU. Furthermore, the International Council for Harmonisation (ICH) guidelines complement these regulations by promoting global harmonization of drug development and approval processes.

Documentation Requirements

Documentation is a cornerstone of the regulatory process, especially when engaging with device partners for generic and combination product development. The key documents required include:

• Common Technical Document (CTD): For both drug and device submissions, the CTD is a standardized format that includes information on administrative, quality, non-clinical, and clinical data.
• Device Master File (DMF): A DMF may be needed to provide details on the manufacturing processes, quality control, and packaging for the device component.
• Clinical Evaluation Report (CER): Essential for combined products, analyzing data from clinical studies relevant to both the drug and device used in the combination therapy.
• Risk Management Plan (RMP): Required to identify, analyze, and mitigate risks associated with the combination product, adhering to ISO 14971 standards.

It is crucial that these documents are meticulously prepared and organized to facilitate smoother interactions with regulatory authorities. Effective RA professionals should align their documentation with specific regulatory expectations and ensure ongoing communication with device partners to gather comprehensive and accurate data.

Review/Approval Flow

The review and approval process for generic and combination products follows a structured pathway that varies across jurisdictions but largely aligns on key stages:

1. Pre-Submission Meetings: Early engagement with regulatory authorities (e.g., FDA, EMA) can provide insights into potential challenges and requirements, particularly for device-dependent products.
2. Submission of Application: Filing for a New Drug Application (NDA), Abbreviated NDA (aNDA) for generics, or Combination Product Application involves rigorous documentation as outlined in the CTD framework.
3. Agency Review: Regulatory agencies evaluate the submitted data against established guidelines. This includes a multifaceted review from CMC, clinical, and quality assurance teams.
4. Advisory Committees: For certain products, expert panels may be convened to provide additional scrutiny and recommendations to the agency.
5. Post-Approval Monitoring: Once a product is authorized, continuous surveillance may be necessitated to ensure compliance with regulatory standards and the safety of the product in real-world use.

Common Deficiencies

Despite thorough planning and documentation, regulatory submissions for generic and combination products can often encounter deficiencies, which may delay the approval process. Some of the most frequently observed issues include:

• Insufficient Bridging Data: When altering product formulations or using new manufacturing processes, it is vital to include bridging data to demonstrate that the updated product is comparable to the previous version.
• Lack of Clarity on Primary Mode of Action: Failing to clearly identify the dominant function of the product (drug, device, or biologic) can result in regulatory ambiguity.
• Inadequate Risk Assessments: Omitting detailed risk assessments that comply with ISO 14971 or not addressing potential hazards related to the combination aspect can lead to significant concerns from regulatory authorities.
• Inconsistent Quality Control Standards: Disparities in quality management systems between drug and device components may raise questions about the product’s overall reliability.

Regulatory Affairs-Specific Decision Points

Several key decision points occur throughout the product development lifecycle that can significantly influence the regulatory pathway, including:

When to File as Variation vs. New Application

Determining whether a change to an existing product constitutes a variation or a new application is critical, especially for combination products. A variation typically involves changes to an already approved product that do not significantly alter its safety profile or intended use. Conversely, a new application is mandated when:

• The changes include a new therapeutic indication.
• There is a substantial alteration in the formulation that may impact the product’s efficacy or safety.
• A new manufacturing process is introduced, especially if it involves novel technology.

Making the correct decision here minimizes submission time and maximizes the efficiency of the approval process.

How to Justify Bridging Data

Bridging data justification is paramount, especially when transitioning from an existing approved product to a new variation or when introducing device changes. Companies should:

• Clearly articulate the differences between the prior product and the proposed changes.
• Include clinical data that demonstrate comparable safety and efficacy profiles.
• Use statistical models to underscore the clinical equivalence if applicable.
• Ensure that all data is integrated into a coherent narrative within the submission documentation.

Conclusion

The journey of developing generic and combination products in collaboration with device partners requires a deep understanding of the regulatory landscape in the US, EU, and UK. Regulatory compliance consulting is not merely a support function but an essential pillar in navigating the intricate challenges associated with special product categories. By leveraging regulatory knowledge, maintaining rigorous documentation, and fostering robust interactions with device partners, pharmaceutical and biotech professionals can streamline the development processes and enhance their likelihood of successful regulatory approvals.